CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
CellServe is developing a novel cardiac cell therapy using specialized stromal cells to treat chronic heart failure. This innovative approach aims to provide a safer and more effective treatment option for patients suffering from severe cardiomyopathy.
Chronic heart failure is a life-threatening disease usually without cure and a leading cause of morbidity and mortality.
In Germany 45 000 patients (projected to EU: about 140 000) die every year from progressive chronic cardiac insufficiency.
There is no curative therapeutic solution, except very rare donor hearts and artificial hearts as bridge devices.Researchers at the Charité - University Medicine, have identified unique cardiac-specific stromal cells (CardAP cells) with strong efficacy in…
CELLSERVE GMBH
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
